News
-
-
PRESS RELEASE
BioNxt Solutions Reports Pending Patent Grants in Europe and Eurasia, Strengthening IP Protection for Proprietary Sublingual Cladribine-Based MS Treatment
BioNxt Solutions Inc. makes significant progress in global patent portfolio with EPO and EAPO confirming acceptance of core claims for sublingual Cladribine thin-film formulation. Focus on innovation in MS treatment -
-
-
-
-
-
-
-
PRESS RELEASE
Capital B: acquisition of 62 BTC for EUR6.2 million, total holding of 2,075 BTC, and BTC Yield of 1,446% YTD
Capital B confirms acquisition of 62 BTC for ~€6.2M, holding 2,075 BTC & BTC Yield of 1,446.3% YTD. Finalizes convertible bond issuance, acquires BTC using proceeds, plans to expand holdings